NO20063655L - Formulering for behandling av fedme og assosiert metabolisk syndrom - Google Patents

Formulering for behandling av fedme og assosiert metabolisk syndrom

Info

Publication number
NO20063655L
NO20063655L NO20063655A NO20063655A NO20063655L NO 20063655 L NO20063655 L NO 20063655L NO 20063655 A NO20063655 A NO 20063655A NO 20063655 A NO20063655 A NO 20063655A NO 20063655 L NO20063655 L NO 20063655L
Authority
NO
Norway
Prior art keywords
formulation
obesity
treatment
metabolic syndrome
extract
Prior art date
Application number
NO20063655A
Other languages
English (en)
Inventor
Marcin Krotkiewski
Original Assignee
Bringwell Internat Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bringwell Internat Ab filed Critical Bringwell Internat Ab
Publication of NO20063655L publication Critical patent/NO20063655L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/77—Sapindaceae (Soapberry family), e.g. lychee or soapberry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Oppfinnelsen angår formuleringer for behandling av fedme og assosierte metabolsk syndrom. Formuleringen er en kombinasjon av spesielt utvalgte vegetabilske ekstrakter: Green tea ekstrakter inneholdende Epigallocatehin galat (EGCG), Coleus forskholii ekstrakt, Betula alba ekstrakt og Guarana eller Yerba Maté ekstrakt. I følge kliniske in vivo og in vitro studier anvendes formuleringen fra oppfinnelsen som verifisert metode for hjelp i behandling av alle kjente former for fedme og assosierte sykeligheter. En av de mest viktige fordelene ved formuleringen fra oppfinnelsen, bortsett fra akselerasjon av vekttap, er forhindring av vektøkning etter avslutning av slankekuren.
NO20063655A 2004-01-15 2006-08-14 Formulering for behandling av fedme og assosiert metabolisk syndrom NO20063655L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PL364411A PL209905B1 (pl) 2004-01-15 2004-01-15 Preparat do leczenia otyłości i związanego z nią syndromu metabolicznego
PCT/EP2005/000206 WO2005067952A1 (en) 2004-01-15 2005-01-12 Formulation for treating obesity and associated metabolic syndrome

Publications (1)

Publication Number Publication Date
NO20063655L true NO20063655L (no) 2006-09-22

Family

ID=34793496

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20063655A NO20063655L (no) 2004-01-15 2006-08-14 Formulering for behandling av fedme og assosiert metabolisk syndrom

Country Status (13)

Country Link
US (1) US20090175969A1 (no)
EP (1) EP1708726B1 (no)
JP (1) JP2007517830A (no)
KR (1) KR100826863B1 (no)
CN (1) CN1946415A (no)
AT (1) ATE411033T1 (no)
AU (1) AU2005205031A1 (no)
CA (1) CA2584191A1 (no)
DE (1) DE602005010387D1 (no)
NO (1) NO20063655L (no)
PL (1) PL209905B1 (no)
RU (1) RU2334523C2 (no)
WO (1) WO2005067952A1 (no)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2883472B1 (fr) * 2005-03-23 2010-09-03 Rocher Yves Biolog Vegetale Utilisation d'un acide chlorogenique en tant qu'un actif amincissant
GB0520956D0 (en) 2005-10-14 2005-11-23 Med Eq As Chewing gum
ES2463090T3 (es) 2005-11-04 2014-05-27 Inqpharm Sdn Bhd Composición a base de plantas para el control del peso
WO2007112996A2 (en) * 2006-03-31 2007-10-11 Dsm Ip Assets B.V. Novel use of compounds and combinations of compunds for improving the physical appearance
EP2079476B1 (en) 2006-10-20 2014-05-21 Dow Global Technologies LLC Uses of hydroxypropyl methylcellulose for preventing or treating metabolic syndrome
WO2008135643A1 (fr) * 2007-05-04 2008-11-13 Nutraceutic Et Business Consulting Composition a activité lipolytique, son procédé d'obtention et utilisation de la composition.
CN102170798B (zh) * 2008-10-03 2013-06-12 西格马食品可变资本有限公司 用于促进对总胆固醇和ldl胆固醇的控制和/或体重减轻和/或生热作用的组合物
RU2465787C1 (ru) * 2008-10-03 2012-11-10 СИГМА АЛИМЕНТОС, С.А. де К.В. Композиция, способствующая регуляции общего холестерина и холестерина лпнп, и/или потере веса, и/или термогенезу
FR2938735B1 (fr) * 2008-11-21 2012-12-28 Holymark Composition amaigrissante, en particulier pour sportifs, administrable par voie orale et complement alimentaire integrant une telle composition.
KR20100124519A (ko) * 2009-05-19 2010-11-29 (주)아모레퍼시픽 녹차 추출물을 함유하는 조성물
CN102370589B (zh) * 2010-08-11 2013-02-13 迪特克(济源)绿色生物科技有限公司 一种减肥霜及其制备方法
JP5815566B2 (ja) 2011-01-21 2015-11-17 ライオン株式会社 脂肪分解促進用組成物
US20130177506A1 (en) * 2011-10-27 2013-07-11 Parker E. Atkins Bio-Available Chlorogenic Acid Preparations for Supplemental Human Consumption and Use
DE102014100534A1 (de) * 2014-01-17 2015-07-23 Pm-International Ag Pulverförmige Zusammensetzung zur Herstellung eines Nahrungsmittelersatzes
US20160310552A1 (en) * 2015-04-24 2016-10-27 Grethe Stoa Birketvedt Northern white kidney bean extract and ceratonia siliqua extract in combination with green tea extract in the treatment of excess weight and obesity
CN107302997A (zh) * 2016-04-19 2017-10-31 林秀霞 一种抑制脂肪蓄积的组合物及其用途
CN107638569A (zh) * 2016-07-21 2018-01-30 上海聿健生物科技有限公司 增强褐色脂肪细胞产热效率的方法和应用
WO2018175417A1 (en) * 2017-03-21 2018-09-27 Pharmachem Laboratories, Llc Controlled release of phaseolamin compositions
WO2019173339A1 (en) * 2018-03-05 2019-09-12 Pure Care Pro Llc Natural combination products and methods for regulation of kidney and excretory system function
KR102267472B1 (ko) * 2018-10-24 2021-06-21 전남대학교산학협력단 녹차 카테킨을 포함하는 중성지방 저감용 식품 조성물, 대사성 질환 개선용 식품 조성물 및 대사성 질환 예방 또는 치료용 약학 조성물
CN113116955B (zh) * 2021-02-24 2022-10-04 中国药科大学 一种含植物提取物的药物组合物及其应用
JP2024008717A (ja) * 2022-07-08 2024-01-19 株式会社常磐植物化学研究所 カフェイン除去マテ抽出物、抗肥満用組成物、カフェイン除去方法及びマテ抽出物の製造方法
KR20240011314A (ko) 2022-07-19 2024-01-26 대구한의대학교산학협력단 과라나 추출물을 포함하는 지방 분화 유도 억제, 지방 합성 억제 및 혈장 콜레스테롤 생성 억제용 조성물, 약학 조성물 및 건강기능식품

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247547A (en) * 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
FR2712191B1 (fr) * 1993-11-08 1996-03-08 Bioes Laboratoires Composition pharmaceutique ou diététique associant du ginseng et du guarana.
US5804596A (en) 1997-02-27 1998-09-08 Sabinsa Corporation Method of preparing a forskohlin composition from forskohlin extract and use of forskohlin for promoting lean body mass and treating mood disorders
JPH10265328A (ja) * 1997-03-27 1998-10-06 Nippon Flour Mills Co Ltd 化粧料、ペットフード、リパーゼ阻害剤及びそれを含む食品
US6143301A (en) * 1998-08-28 2000-11-07 Ambi Inc. Chromium picolinate compositions and uses thereof
JP4783882B2 (ja) * 1999-11-17 2011-09-28 三邦株式会社 新規α−アミラーゼ阻害活性物質、その製造方法及びその用途
US6610749B2 (en) * 2000-02-18 2003-08-26 Arch Development Corporation Polyhydroxylated benzene-containing compounds
ES2225123T3 (es) * 2000-04-04 2005-03-16 Color Access, Inc. Composicion para mejorar la funcion de la barrera lipidica de la piel.
JP4795511B2 (ja) * 2000-07-14 2011-10-19 日本サプリメント株式会社 α−グルコシダーゼ阻害剤の製造法
US6797287B2 (en) * 2001-09-25 2004-09-28 Pharmachem Laboratories, Inc. Phaseolamin compositions and methods for using the same
CA2478663A1 (en) * 2002-03-11 2003-09-18 General Nutrition Investment Company Methods for the treatment and prevention of overweight in mammals
CN1917892A (zh) * 2003-10-24 2007-02-21 草本制药科学有限责任公司 包含冬青的方法和组合物

Also Published As

Publication number Publication date
KR20070009562A (ko) 2007-01-18
CN1946415A (zh) 2007-04-11
PL209905B1 (pl) 2011-11-30
ATE411033T1 (de) 2008-10-15
AU2005205031A1 (en) 2005-07-28
EP1708726A1 (en) 2006-10-11
RU2334523C2 (ru) 2008-09-27
PL364411A1 (en) 2005-07-25
JP2007517830A (ja) 2007-07-05
EP1708726B1 (en) 2008-10-15
CA2584191A1 (en) 2005-07-28
DE602005010387D1 (de) 2008-11-27
KR100826863B1 (ko) 2008-05-06
RU2006129486A (ru) 2008-02-20
WO2005067952A1 (en) 2005-07-28
WO2005067952A8 (en) 2005-11-03
US20090175969A1 (en) 2009-07-09

Similar Documents

Publication Publication Date Title
NO20063655L (no) Formulering for behandling av fedme og assosiert metabolisk syndrom
Oak et al. Potential mechanisms underlying cardiovascular protection by polyphenols: Role of the endothelium
Rodriguez‐Mateos et al. Cranberry (poly) phenol metabolites correlate with improvements in vascular function: A double‐blind, randomized, controlled, dose‐response, crossover study
Wiseman The bioavailability of non-nutrient plant factors: dietary flavonoids and phyto-oestrogens
Okello et al. Inhibition of acetylcholinesterase by green and white tea and their simulated intestinal metabolites
Schini-Kerth et al. Vascular protection by natural product-derived polyphenols: in vitro and in vivo evidence
Pietta et al. Plant polyphenols: Structure, occurrence and bioactivity
Yilmazer-Musa et al. Inhibition of α-amylase and α-glucosidase activity by tea and grape seed extracts and their constituent catechins
Cui et al. Grape seed proanthocyanidin extracts enhance endothelial nitric oxide synthase expression through 5′-AMP activated protein kinase/Surtuin 1–Krüpple like factor 2 pathway and modulate blood pressure in ouabain induced hypertensive rats
Suh et al. Apigenin attenuates 2-deoxy-D-ribose-induced oxidative cell damage in HIT-T15 pancreatic β-cells
R Dias et al. Promising potential of dietary (poly) phenolic compounds in the prevention and treatment of diabetes mellitus
Álvarez-Cilleros et al. Colonic metabolites from flavanols stimulate nitric oxide production in human endothelial cells and protect against oxidative stress-induced toxicity and endothelial dysfunction
Habtemariam Antihyperlipidemic components of Cassia auriculata aerial parts: identification through in vitro studies
Yang et al. Effect of methylated tea catechins from Chinese oolong tea on the proliferation and differentiation of 3T3-L1 preadipocyte
JP5638180B2 (ja) サラシア属植物の抽出物とフラボノイドを含有する食品
IL177219A0 (en) Medicinal acidic cannabinoids
WO2009032888A3 (en) Method for providing energy, relieving stress and mood enhancing benefits comprising administering a composition comprising cholecalciferol and a tea extract
Basly et al. Dietary phytoestrogens: potential selective estrogen enzyme modulators?
Kim et al. Combination treatments with luteolin and fisetin enhance anti-inflammatory effects in high glucose-treated THP-1 cells through histone acetyltransferase/histone deacetylase regulation
CN101006095A (zh) 脂肪酶抑制剂
WO2007056133A3 (en) Herbal composition for weight management
Ahmad et al. Evaluation of anti-osteoporotic activity of butanolic fraction from Passiflora foetida in ovariectomy-induced bone loss in mice
JP2010202558A (ja) 抗肥満剤及び糖尿病改善剤
RU2007118573A (ru) Экстракты солодки голой, обладающие противотуберкулезной активностью
Wiseman Health effects

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application
FC2A Withdrawal, rejection or dismissal of laid open patent application